Tagraxofusp-erzs

(Elzonris)

Tagraxofusp-erzs

Drug updated on 11/16/2023

Dosage FormInjection (intravenous; 1,000 mcg/1 mL)
Drug ClassCD123-directed cytotoxins
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Elzonris (tagraxofusp-erzs) Prescribing Information.2022Stemline Therapeutics, Inc., New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Assessment report: Elzonris. 2021EMA
Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm. 2020Hematology/Oncology Clinics of North America

Clinical Practice Guidelines